S3V Vascular Technologies Limited
₹ 545▲37.97%(150.00)
About the company
S3V Vascular Technologies Limited is an Indian medical device company established in 2011 and headquartered in Mysore, Karnataka. The company specializes in developing and manufacturing innovative cardiovascular and neurovascular medical devices that support minimally invasive procedures. With a strong focus on improving patient outcomes and making advanced healthcare technologies more accessible, S3V is playing an important role in strengthening India's medical device ecosystem.
The company's product portfolio includes drug-eluting stents, PTCA balloon catheters, and a range of advanced devices designed for cardiovascular and neurovascular interventions. These products are developed to help healthcare professionals treat complex conditions such as coronary artery disease, stroke, and other vascular disorders with greater precision and efficiency. By offering high-quality, cost-effective solutions, S3V aims to reduce dependence on imported medical devices while meeting the growing demand for advanced treatment options in India.
Fundamentals
Valuation
- 52 week high
- ₹565
- 52 week low
- ₹350
- P/B ratio
- 7.25
- Debt to equity
- 0.13
- ROE (%)
- 0.04%
- Book value
- ₹77.97
- Face value
- ₹10
- Valuation
- —
Registry
- ISIN number
- INE0HGT01012
Figures in cr
Financials
| P&L Statement | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 21 | 19 | 15 | 13.5 |
| EBITDA | 5.8 | 3.7 | 2.5 | -0.57 |
| OPM | 27.62 | 19.47 | 16.67 | -4.22 |
| PBT | 2.8 | 0.65 | -3.06 | 0.15 |
| PAT | 2.7 | 0.56 | -3.19 | 0.06 |
| EPS | 2.08 | 0.42 | -1.66 | 0.03 |
Shareholding Pattern
Leadership
Frequently asked questions
Common questions on S3V Vascular Technologies Limited—tap a row to read the answer.
Q.1What are S3V Vascular Technologies Limited unlisted shares?
S3V Vascular Technologies Limited unlisted shares are equity shares of the company that are not listed on any recognized stock exchange. These shares are traded through private, off-market transactions and are typically considered by investors looking for exposure to high-growth companies before a potential public listing.
Q.2How can I buy S3V Vascular Technologies Limited unlisted shares?
To invest in S3V Vascular Technologies Limited unlisted shares, you need a valid Demat account and access to a seller offering the shares. Once the price, quantity, and transaction terms are agreed upon, the payment is completed and the shares are transferred electronically to your Demat account through the depository system.
Q.3Is it legal to invest in S3V Vascular Technologies Limited unlisted shares in India?
Yes. Buying and selling unlisted shares is legal in India when the transaction complies with applicable regulations. The transfer should be carried out through authorized depository participants, and all required documentation should be completed to ensure a secure and valid transaction.
Q.4Do I need a Demat account to hold S3V Vascular Technologies Limited unlisted shares?
Yes. A Demat account is required to receive, hold, and transfer unlisted shares electronically. It provides a secure record of ownership and simplifies future transactions if you decide to sell your investment.
Q.5What is the minimum investment required for S3V Vascular Technologies Limited unlisted shares?
There is no fixed minimum investment amount prescribed by the company. The required investment depends on the prevailing share price, the number of shares available for purchase, and the terms agreed upon between the buyer and seller.
Q.6Is there a lock-in period after purchasing S3V Vascular Technologies Limited unlisted shares?
In most cases, there is no mandatory lock-in period for investors purchasing unlisted shares through private transactions. However, if the company is listed on a stock exchange in the future, certain regulatory lock-in provisions may apply to specific categories of shareholders under applicable SEBI regulations.
Trending shares
High-demand unlisted opportunities currently available for trade.
From the blog
Notes on unlisted markets, execution hygiene, and how we think about risk—no hype, no ticker spam.

APTUS PHARMA IPO
Aptus Pharma Limited rolled out its 100% book-built BSE SME public offering worth ₹13.02 Crore. Review crucial parameters for retail investors, featuring the ₹65–₹70 price band, working capital allocations, and an evaluation of its contract-manufacturing partner model.

NEPHROPLUS (NEPHROCARE HEALTH SERVICES) IPO
Explore the Neochem Bio IPO, including issue details, business strengths, risks, and investment analysis.

APOLLO TECHNO INDUSTRIES IPO
Apollo Techno Industries Limited has announced its public offering details. Explore the essential investment parameters for retail and institutional bidders, highlighting the fixed price band, lot structure, key market deadlines, and an overview of its industrial manufacturing footprint.

NEOCHEM BIO IPO
Explore the Neochem Bio IPO, including issue details, business strengths, risks, and investment analysis.

ANONDITA MEDICARE IPO
Anondita Medicare Limited rolled out its 100% book-built SME public offering worth ₹69.50 Crore on the NSE SME platform. Dig into the critical parameters for investors, highlighting the ₹137–₹145 price band, key working capital objectives, and an analysis of its flagship brand 'COBRA' within the growing sexual wellness market.

NEPTUNE LOGITEK IPO
Explore the Neptune Logitek IPO, including issue details, business strengths, risks, and investment analysis.
